Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01875991 · ClinicalTrials.gov registry record · Phase 4
Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
A Phase 4 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 217
- Enrollment target
NCT01875991 is a Phase 4 study that has completed, run by Amgen. The registered enrollment target is 217 participants.
The verdict
NCT01875991, a Phase 4 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 217 participants
- Enrollment target
Study Summary
The study will estimate the preference of rheumatoid arthritis (RA) and Plaque Psoriasis (PsO) patients who self inject etanercept for one of two experimental autoinjectors.
Interventions
- DRUG Etanercept via Autoinjector A
- DRUG Etanercept via Autoinjector B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2013-06-05 |
| Est. Completion | 2014-03-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01875991
The ClinicalTrials.gov registry entry for NCT01875991 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Etanercept via Autoinjector A is the first listed.
NCT01875991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01875991 about?
NCT01875991 is a clinical study titled "Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept". The study will estimate the preference of rheumatoid arthritis (RA) and Plaque Psoriasis (PsO) patients who self inject etanercept for one of two experimental autoinjectors.
What is the current status of trial NCT01875991?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 217 participants. The study started on 2013-06-05. Estimated completion is 2014-03-04.
What interventions are being tested in trial NCT01875991?
The interventions under investigation include: Etanercept via Autoinjector A (DRUG), Etanercept via Autoinjector B (DRUG).
Who is sponsoring clinical trial NCT01875991?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.